Krystal Biotech Inc (KRYS NASDAQ) stock market data APIs
$141.9923
-1.42(-1%)
as of July 8, 2025
Try our APIs with
free plan!
Krystal Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Prev. Close
141.9923
Open
140.5737
High
142.3376
Low
138.9979
52 wk Range
122.8-219.34
Market Cap
4 142 M
P/E Ratio
34.3729
Shares Outstanding
28 899 K
Revenue
333 M
EPS
1.1962
Beta
0.661
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 333 M
- EBITDA: 136 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News
New
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK
PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS), a $4.1 billion biotech company with impressive 93% gross profit margins according to InvestingPro data, has dosed the first patient in its Phase 1/2 c...
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design ...
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Krystal Biotech, Inc. Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss pro...
Exploring High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen by 1.8%, contributing to a 14% increase over the past 12 months, with earnings forecasted to grow by 15% annually. In this favorable environmen...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
